Limitations, agreements, and source contact

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML · Source last updated 2017-08-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

pcarpent@fredhutch.org

organization

Fred Hutchinson Cancer Research Center

phone

(206) 667-5191

title

Dr. Paul A. Carpenter

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice